Sorafenib Plus Chemotherapy Significantly Prolongs Progression-Free Survival in Advanced Breast Cancer Patients.
- Published in:
- Oncology (08909091), 2009, v. 23, n. 11, p. 931
- Publication type:
- Article
Works matching DE "ONYX Pharmaceuticals Inc."
Results: 11
1
2
Voices of Experience.
- Published in:
- 2008
- By:
- Publication type:
- Interview
3
Biomedical briefing.
- Published in:
- Nature Medicine, 2013, v. 19, n. 10, p. 1198, doi. 10.1038/nm1013-1198
- Publication type:
- Article
4
Next-generation proteasome blockers promise safer cancer therapy.
- Published in:
- Nature Medicine, 2012, v. 18, n. 1, p. 7, doi. 10.1038/nm0112-7a
- By:
- Publication type:
- Article
5
News in brief.
- Published in:
- Chemistry & Industry, 2008, n. 23, p. 9
- Publication type:
- Article
6
Multi-kinase inhibitors create buzz at ASCO.
- Published in:
- Nature Biotechnology, 2005, v. 23, n. 6, p. 639, doi. 10.1038/nbt0605-639
- By:
- Publication type:
- Article
7
Market watch.
- Published in:
- Nature, 2007, v. 446, n. 7134, p. 363, doi. 10.1038/446363b
- Publication type:
- Article
8
Amgen swallows Onyx whole.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 10, p. 859, doi. 10.1038/nbt1013-859
- By:
- Publication type:
- Article
9
People.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 3, p. 262, doi. 10.1038/nbt.2535
- Publication type:
- Article
10
Next-generation proteasome inhibitor approved in multiple myeloma.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 11, p. 1011, doi. 10.1038/nbt1112-1011
- By:
- Publication type:
- Article
11
Patient power.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 9, p. 818, doi. 10.1038/nbt.2360
- By:
- Publication type:
- Article